1. Home
  2. REPL vs DPG Comparison

REPL vs DPG Comparison

Compare REPL & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REPL
  • DPG
  • Stock Information
  • Founded
  • REPL 2015
  • DPG 2011
  • Country
  • REPL United States
  • DPG United States
  • Employees
  • REPL N/A
  • DPG N/A
  • Industry
  • REPL Biotechnology: Pharmaceutical Preparations
  • DPG Trusts Except Educational Religious and Charitable
  • Sector
  • REPL Health Care
  • DPG Finance
  • Exchange
  • REPL Nasdaq
  • DPG Nasdaq
  • Market Cap
  • REPL 547.0M
  • DPG 450.4M
  • IPO Year
  • REPL 2018
  • DPG N/A
  • Fundamental
  • Price
  • REPL $5.56
  • DPG $12.66
  • Analyst Decision
  • REPL Buy
  • DPG
  • Analyst Count
  • REPL 10
  • DPG 0
  • Target Price
  • REPL $8.25
  • DPG N/A
  • AVG Volume (30 Days)
  • REPL 24.2M
  • DPG 150.1K
  • Earning Date
  • REPL 08-07-2025
  • DPG 01-01-0001
  • Dividend Yield
  • REPL N/A
  • DPG 9.09%
  • EPS Growth
  • REPL N/A
  • DPG N/A
  • EPS
  • REPL N/A
  • DPG N/A
  • Revenue
  • REPL N/A
  • DPG N/A
  • Revenue This Year
  • REPL N/A
  • DPG N/A
  • Revenue Next Year
  • REPL $194.05
  • DPG N/A
  • P/E Ratio
  • REPL N/A
  • DPG N/A
  • Revenue Growth
  • REPL N/A
  • DPG N/A
  • 52 Week Low
  • REPL $2.68
  • DPG $7.90
  • 52 Week High
  • REPL $17.00
  • DPG $13.58
  • Technical
  • Relative Strength Index (RSI)
  • REPL 44.05
  • DPG 57.92
  • Support Level
  • REPL $4.49
  • DPG $12.57
  • Resistance Level
  • REPL $6.39
  • DPG $12.80
  • Average True Range (ATR)
  • REPL 0.77
  • DPG 0.11
  • MACD
  • REPL 0.09
  • DPG 0.00
  • Stochastic Oscillator
  • REPL 48.77
  • DPG 65.31

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About DPG Duff & Phelps Utility and Infrastructure Fund Inc.

Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting from a high level of current income, with an emphasis on providing tax-advantaged dividend income.

Share on Social Networks: